Kalaris Therapeutics, Inc. (KLRS)
NASDAQ: KLRS · Real-Time Price · USD
2.360
-0.140 (-5.60%)
Oct 9, 2026, 4:00 PM EDT - Market closed
Kalaris Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Cash & Equivalents | 43.17 | 98.05 | 1.64 | 3.17 | 3.06 |
Short-Term Investments | 50.37 | 19.93 | - | - | - |
Cash & Short-Term Investments | 93.54 | 117.98 | 1.64 | 3.17 | 3.06 |
Cash Growth | 5.78% | 7098.41% | -48.28% | 3.60% | - |
Prepaid Expenses | 1.87 | 0.83 | 0.97 | 0.16 | 0.84 |
Total Current Assets | 95.92 | 118.81 | 2.61 | 3.33 | 3.9 |
Property, Plant & Equipment | 1.39 | 1.48 | - | - | - |
Long-Term Deferred Charges | - | - | 3.15 | - | - |
Other Long-Term Assets | 2.23 | 1.45 | 0.41 | - | - |
Total Assets | 99.54 | 121.74 | 6.16 | 3.33 | 3.9 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Accounts Payable | 1.12 | 1.28 | 1.56 | 2.36 | 2.75 |
Accrued Expenses | 7.27 | 8.12 | 2.15 | 1 | 2.52 |
Short-Term Debt | - | - | 19.91 | - | - |
Current Portion of Leases | 0.35 | 0.32 | - | - | - |
Other Current Liabilities | - | - | 1.09 | 0.58 | 0.42 |
Total Current Liabilities | 8.74 | 9.71 | 24.7 | 3.94 | 5.69 |
Long-Term Debt | - | - | - | - | 3.25 |
Long-Term Leases | 1.05 | 1.13 | - | - | - |
Other Long-Term Liabilities | 32.08 | 32.08 | 32.08 | - | 0.26 |
Total Liabilities | 41.87 | 42.92 | 56.78 | 3.94 | 9.21 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Common Stock | 0 | 0 | - | - | - |
Additional Paid-In Capital | 240.11 | 238.81 | 19.95 | 2.38 | 2.42 |
Retained Earnings | -182.37 | -160 | -116.56 | -47.39 | -32.7 |
Comprehensive Income & Other | -0.07 | 0.01 | - | - | - |
Total Common Equity | 57.67 | 78.81 | -96.62 | -45.02 | -30.27 |
Shareholders' Equity | 57.67 | 78.81 | -50.62 | -0.61 | -5.31 |
Total Liabilities & Equity | 99.54 | 121.74 | 6.16 | 3.33 | 3.9 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Total Debt | 1.4 | 1.45 | 19.91 | - | 3.25 |
Net Cash (Debt) | 92.14 | 116.53 | -18.27 | 3.17 | -0.19 |
Net Cash Growth | 4.20% | - | - | - | - |
Net Cash Per Share | 4.30 | 7.63 | -13.67 | 0.52 | -0.04 |
Filing Date Shares Outstanding | 23.8 | 22.93 | 18.7 | 6.76 | 4.44 |
Total Common Shares Outstanding | 23.8 | 22.9 | 6.73 | 6.76 | 4.44 |
Working Capital | 87.18 | 109.1 | -22.1 | -0.61 | -1.79 |
Book Value Per Share | 2.42 | 3.44 | -14.36 | -6.66 | -6.81 |
Tangible Book Value | 57.67 | 78.81 | -96.62 | -45.02 | -30.27 |
Tangible Book Value Per Share | 2.42 | 3.44 | -14.36 | -6.66 | -6.81 |